Skip to main content
SpringerLink
Log in

Vibegron: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Vibegron is a selective beta 3 adrenergic receptor (β3AR) agonist that is being developed in Japan jointly by Kyorin Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd and in other regions worldwide (except in several other Asian countries) by Urovant Sciences for the treatment of overactive bladder (OAB). Based on results from Japanese phase III trials, vibegron received approval in Japan in September 2018 for this indication. This article summarizes the milestones in the development of vibegron leading to this first global approval for the treatment of OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kyorin Pharmaceutical. Beova Tablets 50 mg: Japanese prescribing information. 2018. http://www.info.pmda.go.jp/downfiles/ph/PDF/230109_25900A7F1025_1_02.pdf. Accessed 3 Oct 2018.

  2. Kyorin Pharmaceutical. Kyorin and Kissei signed an agreement for co-development and co-marketing of KRP-114V [media release]. 30 Mar 2016.

  3. Roivant Sciences. Roivant Sciences launches Urovant to develop innovative therapies in urology [media release]. 6 Jun 2017.

  4. Di Salvo J, Nagabukuro H, Wickham LA, et al. Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther. 2017;360(2):346–55.

    Article  Google Scholar 

  5. Urovant Sciences. Pipeline. 2018. https://urovant.com/pipeline/. Accessed 24 Oct 2018.

  6. Kyorin Pharmaceutical. Kyorin signed a license agreement with Merck on vibegron for overactive bladder in Japan [media release]. 22 Jul 2014.

  7. Kyorin Holdings Inc. Kyorin acquired licenses from Merck & Co., Inc., Kenilworth, N.J., U.S.A. for investigational therapy for overactive bladder (Code:KRP-114V) in Asia [media release]. 11 Apr 2017.

  8. Urovant Sciences Ltd SEC filing. 2018. https://www.nasdaq.com/markets/ipos/filing.ashx?filingid=12859913. Accessed 9 Oct 2018.

  9. Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609–23.

    Article  CAS  Google Scholar 

  10. Yoshida M, Kakizaki H, Takahashi S, et al. Long-term safety and efficacy of the novel beta3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study. Int J Urol. 2018;25(7):668–75.

    Article  CAS  Google Scholar 

  11. Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783–90.

    Article  CAS  Google Scholar 

  12. Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.10.006.

    Article  PubMed  Google Scholar 

  13. Dmochowski R, Mitcheson D, Frenkl T, et al. Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: a 52-week phase 2 study in patients with overactive bladder syndrome [abstract no. PD50-03]. J Urol. 2018;199(4 Suppl):e970-e1.

    Google Scholar 

  14. Kyorin Pharmaceutical. Kyorin receives marketing approval in Japan for “Beova® tablets 50 mg” for the treatment of overactive bladder [media release]. 21 Sep 2018.

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Susan J. Keam

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan Keam is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keam, S.J. Vibegron: First Global Approval. Drugs 78, 1835–1839 (2018). https://doi.org/10.1007/s40265-018-1006-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-018-1006-3

Search

Navigation